CAROLINAS HEALTHCARE SYSTEM NORTHEAS
- Type
- Teaching hospital
- Where
- CONCORD, NC
- Medicare CCN
- 340001
- Received
- $5,426,147 in 707 records, 2019 ($410,342 general, $5,015,804 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 106 | $410,342 |
| 2019 | Research payment | 601 | $5,015,804 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 601 | $5,015,804 |
| Space rental or facility fees (teaching hospital only) | 58 | $261,987 |
| Grant | 14 | $53,686 |
| Royalty or License | 4 | $42,782 |
| Gift | 19 | $41,735 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 8 | $6,700 |
| Education | 3 | $3,450 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Stryker Corporation | $11,058 | Gift | In-kind items and services | NSE - BIPOLAR FORCEPS/BIPOLAR GENERATOR Device, NEURO SPINE ENT | 2019 | |
| 2019-12-31 | Stryker Corporation | $6,421 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $5,185 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $4,424 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $3,169 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,508 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $1,593 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $762 | Gift | In-kind items and services | PRIME ELECTRIC W/ ZOOM Device, PATIENT HANDLING - PH | 2019 | |
| 2019-12-31 | Stryker Corporation | $736 | Gift | Cash or cash equivalent | NONE Device, NONE | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $688 | Research payment | In-kind items and services | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2019 | |
| 2019-12-31 | Linvatec Corporation | $280 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $165 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati | 2019 |
| 2019-12-31 | Abbott Laboratories | $70 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-12-30 | Janssen Research & Development, LLC | $12,735 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutami | 2019 | |
| 2019-12-30 | Janssen Research & Development, LLC | $4,741 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutami | 2019 | |
| 2019-12-27 | Janssen Research & Development, LLC | $9,280 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2019 | |
| 2019-12-27 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-12-26 | Cook Incorporated | $2,500 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-23 | Smith+Nephew, Inc. | $10,338 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | REDAPT Revision Hip System Device, Recon Hips | 2019 | |
| 2019-12-23 | ABBVIE INC. | $3,645 | Research payment | Cash or cash equivalent | M14-222 | 2019 | |
| 2019-12-19 | Janssen Research & Development, LLC | $29,495 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Del | 2019 | |
| 2019-12-19 | Edwards Lifesciences Corporation | $29,380 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2019 | |
| 2019-12-19 | Abbott Laboratories | $9,000 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-12-19 | Johnson & Johnson Surgical Vision, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Tecnis Multifocal Family of 1-piece IOLS Device, Optics | 2019 | |
| 2019-12-18 | SEAGEN INC. | $10,140 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-12-18 | Intercept Pharmaceuticals, Inc. | $10,021 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-12-18 | Intercept Pharmaceuticals, Inc. | $5,523 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-18 | SEAGEN INC. | $5,092 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2019 | |
| 2019-12-18 | Cook Research Incorporated | $965 | Research payment | Cash or cash equivalent | Cook Medical Self-Expanding Stent Device, Peripheral Intervention | Zilver PTX V Post Market Study in the US | 2019 |
| 2019-12-18 | Intercept Pharmaceuticals, Inc. | $533 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-17 | Orion Corporation | $2,004 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | 2019 | |
| 2019-12-17 | Shire North American Group Inc | $502 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-16 | Janssen Scientific Affairs, LLC | $48,863 | Research payment | Cash or cash equivalent | INVEGA SUSTENNA Drug, Neuroscience | Impact of paliperidone palmitate on clinical, economic, and psychosocial outcomes in patients with schizophrenia from a | 2019 |
| 2019-12-16 | Edwards Lifesciences Corporation | $18,694 | Research payment | Cash or cash equivalent | Early-TAVR Trial 2016-07 | 2019 | |
| 2019-12-16 | Edwards Lifesciences Corporation | $10,390 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2019 | |
| 2019-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | $30,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NINLARO Drug, Oncology | 2019 | |
| 2019-12-11 | Edwards Lifesciences Corporation | $6,657 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2019 | |
| 2019-12-09 | Shire North American Group Inc | $2,080 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $1,909 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $1,909 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $1,624 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $757 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $50 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $18 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-09 | Shire North American Group Inc | $18 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-06 | Janssen Research & Development, LLC | $18,976 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-12-06 | Genentech, Inc. | $3,950 | Research payment | Cash or cash equivalent | ROZLYTREK Biological, BioOncology | STARTRK 2 RXDX 101 02 | 2019 |
| 2019-12-06 | PFIZER INC. | $2,200 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-12-05 | Olympus Corporation | $22,000 | Research payment | Cash or cash equivalent | Olympus Duodenoscopes Device, GI & Respiratory Products | 2019 | |
| 2019-12-05 | ABBVIE INC. | $10,376 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M14-433 | 2019 |
| 2019-12-05 | ABBVIE INC. | $2,887 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M14-533 | 2019 |
| 2019-12-03 | Intercept Pharmaceuticals, Inc. | $9,994 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-03 | Intercept Pharmaceuticals, Inc. | $2,014 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-02 | SEAGEN INC. | $229,860 | Research payment | In-kind items and services | ADCETRIS Biological, Oncology | A Phase II Trial of PET-Directed Therapy using AVD doxorubicin, vinblastine, and dacarbazine plus Brentuximab Vedotin In | 2019 |
| 2019-12-02 | Janssen Research & Development, LLC | $23,085 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subject | 2019 | |
| 2019-11-28 | Janssen Research & Development, LLC | $3,830 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2019 | |
| 2019-11-27 | ABBVIE INC. | $4,915 | Research payment | Cash or cash equivalent | Skyrizi Biological, Immunology | M16-067 | 2019 |
| 2019-11-27 | ABBVIE INC. | $781 | Research payment | Cash or cash equivalent | M16-534 | 2019 | |
| 2019-11-25 | Intercept Pharmaceuticals, Inc. | $24,625 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-11-25 | Janssen Research & Development, LLC | $19,498 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Del | 2019 | |
| 2019-11-25 | ABBVIE INC. | $4,860 | Research payment | Cash or cash equivalent | M14-222 | 2019 | |
| 2019-11-25 | Intercept Pharmaceuticals, Inc. | $2,009 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-11-25 | GENZYME CORPORATION | $93 | Research payment | Cash or cash equivalent | LEMTRADA Drug, MULTIPLE SCLEROSIS | A Prospective 24-Month Observational Study of Neurocognitive Function and Safety in Patients with Relapsing Multiple Scl | 2019 |
| 2019-11-19 | NuVasive, Inc. | $18,905 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XLIF Device, Spine/Spine Surgery | 2019 | |
| 2019-11-19 | Shire North American Group Inc | $2,080 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $996 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-19 | Shire North American Group Inc | $18 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-18 | Janssen Scientific Affairs, LLC | $24,431 | Research payment | Cash or cash equivalent | INVEGA SUSTENNA Drug, Neuroscience | Impact of paliperidone palmitate on clinical, economic, and psychosocial outcomes in patients with schizophrenia from a | 2019 |
| 2019-11-18 | Roche Products Limited | $11,000 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | AN OPEN LABEL MULTICENTER EXTENSION STUDY | 2019 |
| 2019-11-18 | PFIZER INC. | $5,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-11-18 | GENZYME CORPORATION | $400 | Research payment | Cash or cash equivalent | FABRY-DISEASE Drug | Fabry LSD Data Registry | 2019 |
| 2019-11-18 | GENZYME CORPORATION | $200 | Research payment | Cash or cash equivalent | GAUCHER-DISEASE Drug | Gaucher LSD Data Registry | 2019 |
| 2019-11-18 | GENZYME CORPORATION | $125 | Research payment | Cash or cash equivalent | POMPE - DISEASE Drug | Pompe LSD Data Registry | 2019 |
| 2019-11-16 | Olympus Corporation of the Americas | $25,805 | Grant | In-kind items and services | EVIS EXERA Device, GI & Respiratory Products | 2019 | |
| 2019-11-15 | Allergan, Inc. | $1,500 | Education | Cash or cash equivalent | 2019 | ||
| 2019-11-15 | PFIZER INC. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XALKORI Drug, ONCOLOGY | 2019 | |
| 2019-11-15 | Teleflex Medical Incorporated | $1,100 | Grant | In-kind items and services | PERCUTANEOUS SOLUTIONS: PERCUVANCE & MINILAP BRANDS Device, Surgical | 2019 | |
| 2019-11-14 | Incyte Corporation | $3,174 | Research payment | Cash or cash equivalent | A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroid | 2019 | |
| 2019-11-13 | Novartis Pharmaceuticals Corporation | $6,000 | Research payment | Cash or cash equivalent | GILENYA Drug, NEUROSCIENCE | A 12 MONTH PROSPECTIVE MULTICENTER TWO COHORT NONRANDOMIZED OPEN LABEL STUDY IN ADULT PATIENTS WITH RELAPSING MULTIPLE S | 2019 |
| 2019-11-13 | Abbott Laboratories | $5,456 | Research payment | Cash or cash equivalent | Tendyne Mitral Valve System Device, Cardiac Arrhythmias and Heart Failure | Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Sy | 2019 |
| 2019-11-13 | Orion Corporation | $5,380 | Research payment | Cash or cash equivalent | Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS | 2019 | |
| 2019-11-12 | CSL Behring | $2,000 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Comparison of two infusion devices with respect to Pharmacokinetics, safety and tolerability of Hizentra The Hizentra Go | 2019 |
| 2019-11-12 | CSL Behring | $1,709 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Comparison of two infusion devices with respect to Pharmacokinetics, safety and tolerability of Hizentra The Hizentra Go | 2019 |
| 2019-11-12 | ABBVIE INC. | $1,430 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M14-430 | 2019 |
| 2019-11-12 | CSL Behring | $750 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Comparison of two infusion devices with respect to Pharmacokinetics, safety and tolerability of Hizentra The Hizentra Go | 2019 |
| 2019-11-12 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Comparison of two infusion devices with respect to Pharmacokinetics, safety and tolerability of Hizentra The Hizentra Go | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-12 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-11-11 | Janssen Research & Development, LLC | $9,015 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2019 | |
| 2019-11-11 | Janssen Research & Development, LLC | $3,739 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutami | 2019 | |
| 2019-11-09 | Novartis Pharmaceuticals Corporation | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-11-08 | Bayer Healthcare Pharmaceuticals Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Vitrakvi Drug, Oncology | 2019 | |
| 2019-11-07 | Abbott Laboratories | $2,390 | Research payment | Cash or cash equivalent | Mitra Clip system Device, Cardiac Arrhythmias and Heart Failure | A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of | 2019 |
| 2019-11-06 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,000 | Grant | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2019 | |
| 2019-11-05 | Smith+Nephew, Inc. | $2,245 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Q-FIX Device, Sports Med Shoulder | 2019 | |
| 2019-11-05 | Smith+Nephew, Inc. | $2,204 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Q-FIX Device, Sports Med Shoulder | 2019 | |
| 2019-11-05 | Smith+Nephew, Inc. | $2,039 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Q-FIX Device, Sports Med Shoulder | 2019 | |
| 2019-11-04 | Janssen Research & Development, LLC | $159,587 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-11-04 | Shire North American Group Inc | $11,275 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-04 | Genentech, Inc. | $6,938 | Research payment | Cash or cash equivalent | ROZLYTREK Biological, BioOncology | STARTRK 2 RXDX 101 02 | 2019 |
| 2019-11-04 | ABBVIE INC. | $4,319 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M14-234 | 2019 |
| 2019-11-04 | Shire North American Group Inc | $1,000 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-11-02 | Genentech, Inc. | $9,223 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE IB, OPEN LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY IN COMBINATI | 2019 |
| 2019-11-02 | Novartis Pharmaceuticals Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | 2019 | |
| 2019-10-31 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
| 2019-10-31 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-10-30 | Abbott Laboratories | $15,509 | Research payment | Cash or cash equivalent | HeartMate 3 LVAS Device, Cardiac Arrhythmias and Heart Failure | Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3 Continued Access Protocol | 2019 |
| 2019-10-30 | KLS-Martin L.P. | $11,266 | Royalty or License | Cash or cash equivalent | 2019 | ||
| 2019-10-30 | ABBVIE INC. | $4,132 | Research payment | Cash or cash equivalent | Skyrizi Biological, Immunology | M16-067 | 2019 |
| 2019-10-30 | Boston Scientific Corporation | $1,500 | Grant | Cash or cash equivalent | GENERAL - VASCULAR INTERVENTION Device, VASCULAR | 2019 | |
| 2019-10-30 | ABBVIE INC. | $946 | Research payment | Cash or cash equivalent | M13-576 | 2019 | |
| 2019-10-29 | NuVasive, Inc. | $7,206 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XLIF Device, Spine/Spine Surgery | 2019 | |
| 2019-10-29 | NuVasive, Inc. | $7,170 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XLIF Device, Spine/Spine Surgery | 2019 | |
| 2019-10-28 | Dynavax Technologies Corporation | $16,414 | Research payment | Cash or cash equivalent | Intratumoral SD-101 Drug | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-10-28 | Amgen Inc. | $239 | Research payment | In-kind items and services | Kyprolis Biological, Oncology | P3 Kd v KdD in Relapsed/Refractory MM (CANDOR) | 2019 |
| 2019-10-25 | Janssen Research & Development, LLC | $16,333 | Research payment | Cash or cash equivalent | An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Del | 2019 | |
| 2019-10-25 | Shire North American Group Inc | $2,080 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $1,909 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $1,909 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $1,909 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $690 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $558 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $31 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-25 | Shire North American Group Inc | $18 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-10-24 | Intercept Pharmaceuticals, Inc. | $14,457 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-10-24 | Pharmacyclics LLC, an AbbVie Company | $5,350 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1119-CA | 2019 |
| 2019-10-24 | Intercept Pharmaceuticals, Inc. | $2,792 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-10-24 | E.R. Squibb & Sons, L.L.C. | $300 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase I II PK Safety in Adj Melanoma w New Cell Line | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-21 | Amgen Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XGEVA Biological, Oncology | 2019 | |
| 2019-10-21 | Shire North American Group Inc | $574 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | NON-INTERVENTIONAL POST-MARKETING SAFETY STUDY ON THE LONG-TERM SAFETY OF HYQVIA GLOBAL | 2019 |
| 2019-10-21 | SANOFI US SERVICES INC. | $400 | Research payment | Cash or cash equivalent | KEVZARA Drug, IMMUNOLOGY | GMA LRP PLACEHOLDER - Prospective product registry- PROFILE | 2019 |
| 2019-10-17 | Intercept Pharmaceuticals, Inc. | $51,811 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-10-17 | Edwards Lifesciences Corporation | $26,559 | Research payment | Cash or cash equivalent | Early-TAVR Trial 2016-07 | 2019 | |
| 2019-10-17 | Pharmacyclics LLC, an AbbVie Company | $22,911 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1123-CA | 2019 |
| 2019-10-17 | Intercept Pharmaceuticals, Inc. | $7,580 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2019 |
| 2019-10-17 | Merck Sharp & Dohme LLC | $4,477 | Research payment | Cash or cash equivalent | V934 Drug, ONCOLOGY | A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934,V935 hTERT Vaccination in Cancer Patients | 2019 |
| 2019-10-14 | PFIZER INC. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-10-14 | UCB Biosciences Inc. | $1,012 | Research payment | Cash or cash equivalent | Cimzia Drug, Immunology | A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn' | 2019 |
| 2019-10-11 | Novartis Pharmaceuticals Corporation | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | 2019 | |
| 2019-10-11 | SANOFI-AVENTIS U.S. LLC | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PRALUENT Drug, CARDIOVASCULAR | 2019 | |
| 2019-10-10 | Intercept Pharmaceuticals, Inc. | $32,386 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-10-10 | Edwards Lifesciences Corporation | $1,062 | Research payment | Cash or cash equivalent | The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study 2016-05 | 2019 | |
| 2019-10-09 | KLS-Martin L.P. | $2,799 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-10-08 | E.R. Squibb & Sons, L.L.C. | $19,460 | Research payment | Cash or cash equivalent | EMPLICITI Biological, Oncology | Phase II Study of Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed Multiple Myeloma | 2019 |
| 2019-10-08 | TESARO, Inc. | $11,138 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVA | 2019 | |
| 2019-10-08 | TESARO, Inc. | $9,261 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVA | 2019 | |
| 2019-10-08 | TESARO, Inc. | $4,797 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN ANTI-PD-1 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVA | 2019 | |
| 2019-10-07 | Janssen Research & Development, LLC | $57,865 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2019 | |
| 2019-10-04 | Genentech USA, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Alecensa Biological, BioOncology | 2019 | |
| 2019-10-03 | Olympus America Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Olympus EndoTherapy Accessories Device, EndoTherapy Products | 2019 | |
| 2019-10-02 | Edwards Lifesciences Corporation | $590 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Partner3 2015-08 | 2019 |
| 2019-10-02 | ABBVIE INC. | $474 | Research payment | Cash or cash equivalent | Skyrizi Biological, Immunology | M15-991 | 2019 |
| 2019-10-01 | Roche Products Limited | $2,364 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PPMS | 2019 |
| 2019-10-01 | E.R. Squibb & Sons, L.L.C. | $800 | Research payment | Cash or cash equivalent | Phase I II Safety Expansion | 2019 | |
| 2019-10-01 | SANOFI US SERVICES INC. | $400 | Research payment | Cash or cash equivalent | KEVZARA Drug, IMMUNOLOGY | GMA LRP PLACEHOLDER - Prospective product registry- PROFILE | 2019 |
| 2019-10-01 | TESARO, Inc. | $176 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | PHASE 12 CLINICAL STUDY OF NIRAPARIB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NE | 2019 |
| 2019-09-30 | Janssen Research & Development, LLC | $1,755 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2019 | |
| 2019-09-30 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2019 |
The latest 200 records of 707.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Concord, NC, county Cabarrus County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Concord, NC | County Cabarrus County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 108,719 | 236,133 | 10,730,404 |
| Population, 2020 census P1 | 105,240 | 225,804 | 10,439,388 |
| Median age B01002 | 36.5 | 37.7 | 39.1 |
| Under 18 B01001 | 26.8% | 25.2% | 21.8% |
| 65 and over B01001 | 12.0% | 13.6% | 17.2% |
| Households B11001 | 38,669 | 84,246 | 4,282,345 |
| Foreign born B05002 | 13.5% | 10.8% | 9.1% |
| Median household income B19013 | $86,921 | $89,005 | $72,388 |
| Median family income B19113 | $104,221 | $106,314 | $90,290 |
| Per capita income B19301 | $42,090 | $42,636 | $41,385 |
| Poverty rate B17001 | 9.6% | 9.3% | 13.0% |
| Unemployment rate B23025 | 5.5% | 4.6% | 4.7% |
| Civilian labor force B23025 | 58,255 | 125,285 | 5,336,863 |
| Mean commute (minutes) B08013 | 26.9 | 27.3 | 25.1 |
| Bachelor's degree or higher B15003 | 40.9% | 37.9% | 35.7% |
| Housing units B25001 | 43,142 | 93,691 | 4,895,668 |
| Owner-occupied B25003 | 65.2% | 71.2% | 66.6% |
| Renters B25003 | 34.8% | 28.8% | 33.4% |
| Median home value B25077 | $353,700 | $354,800 | $288,900 |
| Median gross rent B25064 | $1,451 | $1,414 | $1,228 |
| White, not Hispanic B03002 | 49.4% | 57.3% | 60.0% |
| Black B03002 | 22.3% | 18.7% | 20.0% |
| Hispanic or Latino B03002 | 15.8% | 12.7% | 11.3% |
| Asian B03002 | 7.7% | 6.2% | 3.3% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Concord, NC.
Comments